JP2024539090A - 新規トリメタジジン塩 - Google Patents

新規トリメタジジン塩 Download PDF

Info

Publication number
JP2024539090A
JP2024539090A JP2024523404A JP2024523404A JP2024539090A JP 2024539090 A JP2024539090 A JP 2024539090A JP 2024523404 A JP2024523404 A JP 2024523404A JP 2024523404 A JP2024523404 A JP 2024523404A JP 2024539090 A JP2024539090 A JP 2024539090A
Authority
JP
Japan
Prior art keywords
trimetazidine
acid
ppm
pharmaceutical composition
salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024523404A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024539090A5 (enExample
Inventor
マイユ，ジュリアン
ヴィラール，フレデリク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Les Laboratoires Servier SAS
Original Assignee
Les Laboratoires Servier SAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Les Laboratoires Servier SAS filed Critical Les Laboratoires Servier SAS
Publication of JP2024539090A publication Critical patent/JP2024539090A/ja
Publication of JP2024539090A5 publication Critical patent/JP2024539090A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/08—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms
    • C07D295/096—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly bound oxygen or sulfur atoms with the ring nitrogen atoms and the oxygen or sulfur atoms separated by carbocyclic rings or by carbon chains interrupted by carbocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Saccharide Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2024523404A 2021-10-20 2022-10-19 新規トリメタジジン塩 Pending JP2024539090A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP21306465.2 2021-10-20
EP21306465 2021-10-20
PCT/EP2022/079054 WO2023066971A1 (en) 2021-10-20 2022-10-19 Novel trimetazidine salts

Publications (2)

Publication Number Publication Date
JP2024539090A true JP2024539090A (ja) 2024-10-28
JP2024539090A5 JP2024539090A5 (enExample) 2025-11-06

Family

ID=78592764

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024523404A Pending JP2024539090A (ja) 2021-10-20 2022-10-19 新規トリメタジジン塩

Country Status (20)

Country Link
US (1) US20250250245A1 (enExample)
EP (1) EP4419510B1 (enExample)
JP (1) JP2024539090A (enExample)
KR (1) KR20240093576A (enExample)
CN (1) CN118076591A (enExample)
AR (1) AR127403A1 (enExample)
AU (1) AU2022369026A1 (enExample)
CR (1) CR20240157A (enExample)
DK (1) DK4419510T3 (enExample)
ES (1) ES3057370T3 (enExample)
HR (1) HRP20251413T1 (enExample)
IL (1) IL311916A (enExample)
LT (1) LT4419510T (enExample)
MA (1) MA66951B1 (enExample)
MX (1) MX2024004714A (enExample)
PL (1) PL4419510T3 (enExample)
PT (1) PT4419510T (enExample)
RS (1) RS67449B1 (enExample)
SI (1) SI4419510T1 (enExample)
WO (1) WO2023066971A1 (enExample)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025106477A1 (en) * 2023-11-14 2025-05-22 Samsara Therapeutics Inc. Novel autophagy inducing compounds and uses thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105287564A (zh) * 2015-09-06 2016-02-03 余祖江 一种防治肝病的西药复合物及其用途
CN110054599A (zh) * 2019-05-14 2019-07-26 中南民族大学 一种曲美他嗪草酸盐及其制备方法和应用
CN112043691A (zh) * 2019-06-06 2020-12-08 常州高新技术产业开发区三维工业技术研究所有限公司 一种药物组合物及其用途

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104138376A (zh) * 2013-05-06 2014-11-12 常州高新技术产业开发区三维工业技术研究所有限公司 一种提高缺氧耐受力的缓释剂
FR3027803B1 (fr) 2014-11-05 2018-02-09 Les Laboratoires Servier Composition pharmaceutique comprenant un betabloquant et un inhibiteur de l'enzyme de conversion
CN110183398B (zh) 2019-05-14 2021-06-29 中南民族大学 一种曲美他嗪草酸盐及其制备方法和应用
CN110105307B (zh) 2019-05-14 2021-06-01 中南民族大学 一种曲美他嗪草酸盐及其制备方法和应用

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105287564A (zh) * 2015-09-06 2016-02-03 余祖江 一种防治肝病的西药复合物及其用途
CN110054599A (zh) * 2019-05-14 2019-07-26 中南民族大学 一种曲美他嗪草酸盐及其制备方法和应用
CN112043691A (zh) * 2019-06-06 2020-12-08 常州高新技术产业开发区三维工业技术研究所有限公司 一种药物组合物及其用途

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
芦澤一英, 医薬品の多形現象と晶析の化学, JPN6015027444, 2002, pages 273 - 278, ISSN: 0005903839 *

Also Published As

Publication number Publication date
IL311916A (en) 2024-06-01
CR20240157A (es) 2024-05-22
EP4419510B1 (en) 2025-10-08
ES3057370T3 (en) 2026-03-02
WO2023066971A1 (en) 2023-04-27
LT4419510T (lt) 2025-12-29
CN118076591A (zh) 2024-05-24
CA3234743A1 (en) 2023-04-27
US20250250245A1 (en) 2025-08-07
RS67449B1 (sr) 2025-12-31
AR127403A1 (es) 2024-01-17
KR20240093576A (ko) 2024-06-24
EP4419510A1 (en) 2024-08-28
HRP20251413T1 (hr) 2025-12-19
MA66951B1 (fr) 2025-12-31
AU2022369026A1 (en) 2024-05-02
PT4419510T (pt) 2026-01-02
SI4419510T1 (sl) 2026-01-30
MX2024004714A (es) 2024-05-10
DK4419510T3 (da) 2025-11-17
PL4419510T3 (pl) 2026-02-16

Similar Documents

Publication Publication Date Title
US20100267783A1 (en) Pharmaceutical composition containing optically active compound having thrombopoietin receptor agonist activity, and intermediate therefor
CN113735834A (zh) 普那布林组合物
US20250361218A1 (en) Agents and methods for treating dysproliferative diseases
US9359328B2 (en) 2-[[[2-[(hydroxyacetyl)amino]-4-pyridinyl]methyl]thio]-N-[4-(trifluoromethoxy)phenyl]-3-pyridinecarboxamide benzenesulfonate, crystal of same, crystal polymorph thereof, and methods for production thereof
JPH06506443A (ja) アザ二環式およびアザ三環式誘導体、その製法および中間体ならびに該化合物含有の医薬組成物
US20250250245A1 (en) Trimetazidine salts
KR20220148860A (ko) 2-[(4s)-8-플루오로-2-[4-(3-메톡시페닐)피페라진-1-일]-3-[2-메톡시-5-(트리플루오로메틸)페닐]-4h-퀴나졸린-4-일]아세트산의 칼륨 염
CA3234743C (en) Novel trimetazidine salts
KR100830002B1 (ko) 시부트라민의 무기산염
AU2021225363B2 (en) A method of producing a crystalline form of sodium 2-[(4S)-8-fluoro-2-[4-(3-methoxyphenyl)piperazin-1-yl]-3-[2-methoxy-5-(trifluoromethyl)phenyl]-4H-quinazolin-4-yl]acetate trihydrate
HK40115749A (en) Novel trimetazidine salts
HK40115749B (en) Novel trimetazidine salts
KR20260070540A (ko) 환원형 β-니코틴아미드 모노뉴클레오티드 칼슘염의 다형체 및 이의 제조 방법과 용도
EA048901B1 (ru) Новые соли триметазидина
KR20250169304A (ko) 신규 트리메타지딘 고체 상
WO2006128389A1 (en) Purine derivatives
HK40130959A (en) Novel trimetazidine solid phases
HK40108623A (en) Novel trimetazidine salts
JPWO2007063821A1 (ja) 光学活性なジヒドロピリジン誘導体の酸付加塩
SK572003A3 (en) Crystalline therapeutic agent
JPH11292879A (ja) カルボキサミド誘導体
JP2008290988A (ja) 光学活性なジヒドロピリジン誘導体の酸付加塩を含有する医薬
WO2025191534A1 (en) Solid state forms of zasocitinib and process for preparation thereof
RU2773843C1 (ru) Композиции плинабулина
EP4698277A1 (en) Solid state forms of fosgonimeton and salts thereof

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251017

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251028

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260707